🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jing Luo

Yangtze University

ORCID: 0000-0002-1190-553X

Also affiliated with Xiangyang Central Hospital

MedicineEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.818Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Impact of COVID-19-related regulatory changes on nationwide access to buprenorphine: An interrupted time series design

Drug and Alcohol Dependence Reports(2023)10.1016/j.dadr.2023.100135
Top 25%
0.818DataRank
Top 25%12 citations

Katherine Callaway Kim, Katie J. Suda, Jing Luo, Xiaoming Wang, Donna Olejniczak +2 more

Papers

Driven by 11 papers — median percentile 75. Top paper: “Impact of COVID-19-related regulatory changes on nationwide access to buprenorphine: An interrupted time series design”.

Impact of COVID-19-related regulatory changes on nationwide access to buprenorphine: An interrupted time series design

Drug and Alcohol Dependence Reports(2023)10.1016/j.dadr.2023.100135
Top 25%
0.818DataRank
Top 25%12 citations

Katherine Callaway Kim, Katie J. Suda, Jing Luo, Xiaoming Wang, Donna Olejniczak +2 more

Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program

JAMA Network Open(2020)10.1001/jamanetworkopen.2020.20969
N/A
0.691DataRank · unranked
99 citations

Robert Feldman, Scott D. Rothenberger, Inmaculada Hernandez, Walid F. Gellad, Jing Luo

A machine learning approach identifies modulators of heart failure hospitalization prevention among patients with type 2 diabetes: A revisit to the ACCORD trial

Journal of Diabetes and its Complications(2022)10.1016/j.jdiacomp.2022.108287
N/A
0.345DataRank · unranked
9 citations

Jingchuan Guo, Yilu Lin, Jing Luo, William C. Cushman, Lizheng Shi +3 more

Insulin access and affordability in the USA: anticipating the first interchangeable insulin product

The Lancet Diabetes & Endocrinology(2020)10.1016/s2213-8587(20)30105-4
N/A
0.312DataRank · unranked
7 citations

Aaron S. Kesselheim, Ameet Sarpatwari, Jing Luo

Rural-Urban Disparities in the Uptake of New Diabetes Medications

Diabetes Spectrum(2024)10.2337/ds23-0075
N/A
0.219DataRank · unranked
3 citations

Ding Dong, Jing Luo, Sherry Glied, Benjamin Zhu

Buprenorphine dispensing before and after the April 2021 X-Waiver exemptions: An interrupted time series analysis

International Journal of Drug Policy(2024)10.1016/j.drugpo.2024.104381
N/A
0DataRank · unranked
36 citations

Katie J. Suda, Jing Luo, MyoungKeun Lee, Joel Anderton, Donna Olejniczak +2 more

Changes in Buprenorphine Prescribing After X-Waiver Exemptions: An Interrupted Time Series Analysis

Drug and Alcohol Dependence(2024)10.1016/j.drugalcdep.2023.110167
N/A
0DataRank · unranked
0 citations

Katie J. Suda, Jing Luo, MyoungKeun Lee, Joel Anderton, Donna Olejniczak +2 more

MicroRNA-301a (miR-301a) is induced in hepatocellular carcinoma (HCC) and down- regulates the expression of interferon regulatory factor-1

Biochemical and Biophysical Research Communications(2020)10.1016/j.bbrc.2020.01.034
N/A
0DataRank · unranked
16 citations

Qiang Du, Xiao Cui, Peiqi Wan, Christof Kaltenmeier, Jing Luo +4 more

Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes

Diabetes Research and Clinical Practice(2022)10.1016/j.diabres.2022.109855
N/A
0DataRank · unranked
12 citations

Nico Gabriel, Mary T. Korytkowski, Inmaculada Hernandez, Walid F. Gellad, Jing Luo

Real‐world weight‐loss effectiveness of glucagon‐like peptide‐1 agonists among patients with type 2 diabetes: A retrospective cohort study

Obesity(2023)10.1002/oby.23622
N/A
0DataRank · unranked
62 citations

Ingrid Shu, David Rometo, Jon A. Arnold, Mary T. Korytkowski, Jing Luo +1 more

Implementing real-time prescription benefit tools: Early experiences from 5 academic medical centers

Healthcare(2023)10.1016/j.hjdsi.2023.100689
N/A
0DataRank · unranked
10 citations

Rachel Wong, Tanvi Mehta, Jeremy I. Schwartz, Jeremy A. Epstein, Erika Cornelius Smith +6 more